Citation: Mx. He et al., Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s, DRUG META D, 29(5), 2001, pp. 701-711
Authors:
Yao, CP
Kunze, KL
Kharasch, ED
Wang, Y
Trager, WF
Ragueneau, I
Levy, RH
Citation: Cp. Yao et al., Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2, CLIN PHARM, 70(5), 2001, pp. 415-424
Authors:
Rao, S
Aoyama, R
Schrag, M
Trager, WF
Rettie, A
Jones, JP
Citation: S. Rao et al., A refined 3-dimensional QSAR of cytochrome P4502C9: Computational predictions of drug interactions, J MED CHEM, 43(15), 2000, pp. 2789-2796
Authors:
Erickson, DA
Mather, G
Trager, WF
Levy, RH
Keirns, JJ
Citation: Da. Erickson et al., Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450, DRUG META D, 27(12), 1999, pp. 1488-1495
Authors:
Koenigs, LL
Peter, RM
Hunter, AP
Haining, RL
Rettie, AE
Friedberg, T
Pritchard, MP
Shou, M
Rushmore, TH
Trager, WF
Citation: Ll. Koenigs et al., Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9, BIOCHEM, 38(8), 1999, pp. 2312-2319
Citation: Rl. Haining et al., Enzymatic determinants of the substrate specificity of CYP2C9: Role of B '-C loop residues in providing the pi-stacking anchor site for warfarin binding, BIOCHEM, 38(11), 1999, pp. 3285-3292
Citation: Mx. He et al., Structural forms of phenprocoumon and warfarin that are metabolized at theactive site of CYP2C9, ARCH BIOCH, 372(1), 1999, pp. 16-28
Citation: C. Audergon et al., Experimental and theoretical study of the effect of active-site constrained substrate motion on the magnitude of the observed intramolecular isotope effect for the P450 101 catalyzed benzylic hydroxylation of isomeric xylenes and 4,4 '-dimethylbiphenyl, J AM CHEM S, 121(1), 1999, pp. 41-47